50 research outputs found
Weak localization and conductance fluctuations of a chaotic quantum dot with tunable spin-orbit coupling
In a two-dimensional quantum dot in a GaAs heterostructure, the spin-orbit
scattering rate is substantially reduced below the rate in a bulk
two-dimensional electron gas [B.I. Halperin et al, Phys. Rev. Lett. 86, 2106
(2001)]. Such a reduction can be undone if the spin-orbit coupling parameters
acquire a spatial dependence, which can be achieved, e.g., by a metal gate
covering only a part of the quantum dot. We calculate the effect of such
spatially non-uniform spin-orbit scattering on the weak localization correction
and the universal conductance fluctuations of a chaotic quantum dot coupled to
electron reservoirs by ballistic point contacts, in the presence of a magnetic
field parallel to the plane of the quantum dot.Comment: 4 pages, RevTeX; 2 figures. Substantial revision
T1 mapping shows increased extracellular matrix size in the myocardium due to amyloid depositions
Improved survival beyond 28 days up to 1 year after cytosorb treatment for refractory septic shock: A propensity-weighted retrospective survival analysis
Background and Aims: It is currently unknown whether CytoSorb treatment for septic shock improves long-term survival beyond 28 days
Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: A propensity-score-weighted retrospective study
Background and aims: Innovative treatment modalities have not yet shown a clinical benefit in patients with septic shock. To reduce severe cytokinaemia, CytoSorb as an add-on to continuous renal replacement therapy (CRRT) showed promising results in case reports. However, there are no clinical trials investigating outcomes. Methods: In this investigator-initiated retrospective study, patients with septic shock were treated with CRRT + CytoSorb (n = 67) or CRRT alone (n = 49). The primary outcome was the 28-day all-cause mortality rate. Patients were weighted by stabilized inverse probability of treatment weights (sIPTW) to overcome differences in baseline characteristics. Results: At the start of therapy, CytoSorb-treated patients had higher lactate levels (p < 0.001), lower mean arterial pressure (p = 0.007) and higher levels of noradrenaline (p < 0.001) compared to the CRRT group. For CytoSorb, the mean predicted mortality rate based on a SOFA of 13.8 (n = 67) was 75% (95%CI 71-79%), while the actual 28-day mortality rate was 48% (mean difference - 27%, 95%CI - 38 to - 15%, p < 0.001). For CRRT, based on a SOFA of 12.8 (n = 49), the mean predicted versus observed mortality was 68% versus 51% (mean difference - 16.9% [95%CI - 32.6 to - 1.2%, p = 0.035]). By sIPTW analysis, patients treated with CytoSorb had a significantly lower 28-day mortality rate compared to CRRT alone (53% vs. 72%, respectively, p = 0.038). Independent predictors of 28-day mortality in the CytoSorb group were the presence of pneumosepsis (adjusted odds ratio [aOR] 5.47, p = 0.029), higher levels of lactate at the start of CytoSorb (aOR 1.15, p = 0.031) and older age (aOR per 10 years 1.67, p = 0.034). Conclusions: CytoSorb was associated with a decreased observed versus expected 28-day all-cause mortality. By IPTW analysis, intervention with CytoSorb may be associated with a decreased all-cause mortality at 28 days compared to CRRT alone
Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study
Background. (Pegylated) Interferon ([Peg]IFN) therapy leads to response in a minority of chronic hepatitis B (CHB) patients.
Host genetic determinants of response are therefore in demand.
Methods. In this genome-wide association study (GWAS), CHB patients, treated with (Peg)IFN for at least 12 weeks ± nucleos(t)ide analogues within randomized trials or as standard of care, were recruited at 21 centers from Europe, Asia, and North
America. Response at 24 weeks after (Peg)IFN treatment was defined as combined hepatitis B e antigen (HBeAg) loss with hepatitis
B virus (HBV) DNA <2000 IU/mL, or an HBV DNA <2000 IU/mL for HBeAg-negative patients.
Results. Of 1144 patients, 1058 (92%) patients were included in the GWAS analysis. In total, 282 (31%) patients achieved the
response and 4% hepatitis B surface antigen (HBsAg) loss. GWAS analysis stratified by HBeAg status, adjusted for age, sex, and the
4 ancestry components identified PRELID2 rs371991 (B= −0.74, standard error [SE] = 0.16, P = 3.44 ×10–6) for HBeAg-positive
patients. Importantly, PRELID2 was cross-validated for long-term response in HBeAg-negative patients. G3BP2 rs3821977 (B = 1.13,
SE = 0.24, P = 2.46 × 10–6) was associated with response in HBeAg-negative patients. G3BP2 has a role in the interferon pathway and
was further examined in peripheral blood mononuclear cells of healthy controls stimulated with IFNα and TLR8. After stimulation,
less production of IP-10 and interleukin (IL)-10 proteins and more production of IL-8 were observed with the G3BP2 G-allele.
Conclusions. Although no genome-wide significant hits were found, the current GWAS identified genetic variants associated
with (Peg)IFN response in CHB. The current findings could pave the way for gene polymorphism-guided clinical counseling, both
in the setting of (Peg)IFN and the natural history, and possibly for new immune-modulating therapies
Orbital and spin contributions to the -tensors in metal nanoparticles
We present a theoretical study of the mesoscopic fluctuations of -tensors
in a metal nanoparticle. The calculations were performed using a semi-realistic
tight-binding model, which contains both spin and orbital contributions to the
-tensors. The results depend on the product of the spin-orbit scattering
time and the mean-level spacing , but are
otherwise weakly affected by the specific shape of a {\it generic}
nanoparticle. We find that the spin contribution to the -tensors agrees with
Random Matrix Theory (RMT) predictions. On the other hand, in the strong
spin-orbit coupling limit , the
orbital contribution depends crucially on the space character of the
quasi-particle wavefunctions: it levels off at a small value for states of
character but is strongly enhanced for states of character. Our numerical
results demonstrate that when orbital coupling to the field is included, RMT
predictions overestimate the typical -factor of orbitals that have dominant
-character. This finding points to a possible source of the puzzling
discrepancy between theory and experiment.Comment: 21 pages, 6 figures; accepted for publication in Physical Review
Current induced switching of magnetic domains to a perpendicular configuration
In a ferromagnet--normal-metal--ferromagnet trilayer, a current flowing
perpendicularly to the layers creates a torque on the magnetic moments of the
ferromagnets. When one of the contacts is superconducting, the torque not only
favors parallel or antiparallel alignment of the magnetic moments, as is the
case for two normal contacts, but can also favor a configuration where the two
moments are perpendicular. In addition, whereas the conductance for parallel
and antiparallel magnetic moments is the same, signalling the absence of giant
magnetoresistance in the usual sense, the conductance is greater in the
perpendicular configuration. Thus, a negative magnetoconductance is predicted,
in contrast with the usual giant magnetoresistance.Comment: 4 pages, 3 figures, major rewriting of the technical par
Unique intrahepatic transcriptomics profiles discriminate the clinical phases of a chronic HBV infection
Chronic hepatitis B is a highly heterogeneous liver disease characterized by phases with fluctuations in viral replication and progressive liver damage in some, but not all infected individuals. Despite four decades of research, insight into host determinants underlying these distinct clinical phases-immunotolerant, immune active, inactive carrier, and HBeAg-negative hepatitis±remains elusive. We performed an in-depth transcriptome analysis of archived FFPE liver biopsies of each clinical phase to address host determinants associated with the natural history. Therefore, we determined, for the first time, intrahepatic global expression profiles of well-characterized chronic HBV patients at different clinical phases. Our data, obtained by microarray, demonstrate that B cells and NK/cytotoxicrelated genes in the liver, including CD19, TNFRSF13C, GZMH, and KIR2DS3, were differentially expressed across the clinical HBV phases, which was confirmed by modular analysis and also Nanostring arrays in an independent cohort. Compared to the immunotolerant phase, 92 genes were differentially expressed in the liver during the immune active phase, 46 in the inactive carrier phase, and 71 in the HBeAg-negative phase. Furthermore, our study also revealed distinctive transcription of genes associated with cell cycle activity, NF-κB signaling, cytotoxic function and mitochondrial respiration between clinical phases. Our data define for the first time using microarray unique transcriptomes in the HBV-infected liver during consecutive clinical phases. We demonstrate that fluctuations of viral loads and liver damage coincide with fluctuations in the liver transcriptome and point to functionalimmune and non-immune-components contributing to the clinical phenotype in patients
Prediction of long-term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE-B score
An abundance of noninvasive scores have been associated with fibrosis and hepatocellular carcinoma (HCC) development. We aimed to compare the prognostic ability of these scores in relation to liver histology in chronic hepatitis B (CHB) patients. Liver biopsies from treatment-naïve CHB patients at one tertiary care centre were scored by a single hepato-pathologist. Laboratory values at liver biopsy were used to calculate the PAGE-B, REACH-B, GAG-HCC, CU-HCC and FIB-4 scores. Any clinical event was defined as HCC development, liver failure, transplantation and mortality. HCC and mortality data were obtained from national database registries. Of 557 patients, 40 developed a clinical event within a median follow-up of 10.1 (IQR 5.7-15.9) years. The PAGE-B score predicted any clinical event (C-statistic.86, 95% CI: 0.80-0.92), HCC development (C-statistic.91) and reduced transplant-free survival (C-statistic.83) with good accuracy, also when stratified by ethnicity, antiviral therapy after biopsy or advanced fibrosis. The C-statistics (95% CI) of the REACH-B, GAG-HCC, CU-HCC and FIB-4 scores for any event were.70 (0.59-0.81),.82 (0.75-0.89),.73 (0.63-0.84) and.79 (0.69-0.89), respectively. The PAGE-B event risk assessment improved modestly when combined with the Ishak fibrosis stage (C-statistic.87, 95% CI: 0.82-0.93). The PAGE-B score showed the best performance in assessing the likelihood of developing a clinical event among a diverse CHB population over 15 years of follow-up. Additional liver histological characteristics did not appear to provide a clinically significant improvement
ITPA polymorphisms are associated with hematological side effects during antiviral therapy for chronic HCV infection
Background/Objective Genetic polymorphisms in the inosine triphosphatase (ITPA) gene have been associated with the protection from early ribavirin(RBV)-induced hemolytic anemia among patients with chronic hepatitis C virus (HCV) infection. The aim of the present study was to investigate the association between the functional ITPA variants and hematological side effects during antiviral therapy with pegylated interferon (PegIFN) and RBV. Patients and Methods This cohort study included all consecutive Caucasian patients treated for chronic HCV infection with PegIFN and RBV between 2000 and 2009 for whom a serum sample was available for genetic testing. The predicted inosine triphosphate pyrophosphatase (ITPase) activity was based on the genotypes of the SNPs rs1127354 and rs7270101. Decline in hemoglobin (Hb) during antiviral therapy, as well as dose reductions, blood transfusions and use of erythropoietin were assessed. Results In total, 213 patients were included. The predicted ITPase activity was normal among 152 (71%) patients; 61 (29%) patients had ITPase deficiency. By multivariable linear regression, RBV dose in mg per kilogram (Beta 0.09, 95%CI 0.04-0.13, p<0.001) and normal ITPase activity (Beta 0.89, 95%CI 0.64-1.14, p<0.001) were associated with more Hb decline at week 4 of treatment. Patients with normal ITPase activity underwent more dose adjustments of RBV than patients with ITPase deficiency (19(13%) vs 1(2%),p = 0.014) and received erythropoietin more frequently (12 (8%) vs 0 (0%),p = 0.024). Conclusion Genetic variants in the ITPA gene protected against RBV treatment-induced anemia among Caucasian patients with chronic HCV infection. Patients with normal ITPase activity underwent more dose reductions of RBV and received erythropoietin more frequently